SCHEMBL4334753

SCHEMBL4334753

O=C(O)c1cccn1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.46
POLB P06746 1/20 0.46
APEX1 P27695 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
HDAC9 Q9UKV0 1/20 0.42
HDAC5 Q9UQL6 1/20 0.42
ALDH1A1 P00352 4/20 0.36
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
ALOX12 P18054 1/20 0.36
RECQL P46063 1/20 0.36
KMT2A Q03164 1/20 0.36
DAO P14920 2/20 0.35
TSHR P16473 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4904690 0.86 TDP1 (0.43) TDP1POLBAPEX1L3MBTL1HDAC4
SCHEMBL4379296 0.82 POLB (0.43) TDP1POLBAPEX1L3MBTL1HDAC4
SCHEMBL14398922 0.79 POLB (0.41) TDP1POLBAPEX1L3MBTL1HDAC4
SCHEMBL4905375 0.77 POLB (0.40) TDP1POLBAPEX1L3MBTL1HDAC4
SCHEMBL28614024 0.77 POLB (0.40) TDP1POLBAPEX1L3MBTL1HDAC4
SCHEMBL6794236 0.77 L3MBTL1 (0.40) TDP1POLBAPEX1L3MBTL1HDAC4
SCHEMBL4913277 0.77 POLB (0.40) TDP1POLBAPEX1L3MBTL1HDAC4
SCHEMBL20916949 0.74 BCHE (0.46) TDP1POLBAPEX1L3MBTL1HDAC8
SCHEMBL26119733 0.74 LPO (0.45) TDP1POLBAPEX1L3MBTL1ALDH1A1
SCHEMBL161488 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119371694-A Light high-strength heat-resistant stab-resistant fiber composite material and preparation method thereof 中国工程物理研究院化工材料研究所 2025-01-28 CN claimed
CN-102153558-A Derivative of multi-target antitumor inhibitor 2-aminopyrrole-triazine and synthesis method thereof YANGZHOU YONGJI MEDICAL NEW TECHNOLOGY CO LTD 2011-08-17 CN claimed
CN-1829507-A Tyrosine kinase inhibitors MERCK & CO INC (US) 2006-09-06 CN claimed
EP-4504341-A1 COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE Shy Therapeutics LLC (US) 2025-02-12 EP disclosed
US-12215116-B2 Arginase inhibitors and methods of use MERCK SHARP & DOHME LLC (US) 2025-02-04 US disclosed
CN-119371694-A Light high-strength heat-resistant stab-resistant fiber composite material and preparation method thereof 中国工程物理研究院化工材料研究所 2025-01-28 CN disclosed
WO-2023196975-A1 COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE SHY THERAPEUTICS, LLC (US) 2023-10-12 WO disclosed
WO-2023107597-A2 BICYCLIC HETEROAROMATIC AMIDE COMPOUNDS AND USES THEREOF Kineta, Inc. (US) 2023-06-15 WO disclosed
CN-114173787-A Dihydropyrimidine derivatives and their use in the treatment of HBV infection or HBV-induced diseases 杨森科学爱尔兰无限公司 2022-03-11 CN disclosed
CN-114057747-A Dual inhibitors and uses thereof 贝达药业股份有限公司 2022-02-18 CN disclosed
CN-104292146-B Telaprevir intermediate and preparation method thereof 上海医药工业研究院 2017-04-26 CN disclosed
WO-2006020664-A2 AMMONOLYSIS PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR DPP IV INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-02-23 WO disclosed
US-20060035954-A1 Ammonolysis process for the preparation of intermediates for DPP IV inhibitors BRISTOL-MYERS SQUIBB COMPANY 2006-02-16 US disclosed
US-20050271975-A1 Films with photoresponsive wettability WORCESTER POLYTECHNIC INSTITUTE (US) 2005-12-08 US disclosed
US-20050256019-A1 Enzymatic ammonolysis process for the preparation of intermediates for DPP IV inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-11-17 US disclosed
WO-2005108594-A1 ENZYMATIC AMMONOLYSIS PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR DPP IV INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-11-17 WO disclosed
EP-1581487-A2 METHODS AND COMPOUNDS PRODUCING DIPEPTIDYL PEPTIDASE IV INHIBITORS AND INTERMEDIATES THEREOF Bristol-Myers Squibb Company (US) 2005-10-05 EP disclosed
WO-2005059060-A1 FILMS WITH PHOTORESPONSIVE WETTABILITY WORCESTER POLYTECHNIC INSTITUTE (US) 2005-06-30 WO disclosed
WO-2004052850-A2 METHODS AND COMPOUNDS PRODUCING DIPEPTIDYL PEPTIDASE IV INHIBITORS AND INTERMEDIATES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2004-06-24 WO disclosed
US-4048191-A Halo-substituted 1-loweralkyl-5-aroylpyrrole-2-acetic acid compounds MCNEIL LABORATORIES, INCORPORATED (US) 1977-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035954-A1 Ammonolysis process for the preparation of intermediates for DPP IV inhibitors DPP4, DPP8, DPP7 TDP1 301/4885POLB 646/4885APEX1 1862/4885
US-12215116-B2 Arginase inhibitors and methods of use ARG1, ARG2, PRMT1 TDP1 1482/4885POLB 2133/4885APEX1 2209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.